Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25677246 | 0.86 | CD274 (0.40) | CNR2LRRK2 | |
| SCHEMBL4726744 | 0.85 | GPR119 (0.50) | CNR2GPR119ALOX5APFEN1 | |
| SCHEMBL17797653 | 0.80 | KMT2A (0.46) | GPR119ACACBOXTRAVPR1AEHMT2 | |
| SCHEMBL17196816 | 0.76 | ALOX5AP (0.42) | GPR119ALOX5APFEN1NAMPT | |
| SCHEMBL17196879 | 0.76 | PIK3CD (0.44) | GPR119 | |
| SCHEMBL22797267 | 0.74 | OXTR (0.42) | GPR119OXTRAVPR1ANAMPT | |
| SCHEMBL25113635 | 0.74 | GPR119 (0.49) | GPR119 | |
| SCHEMBL14230857 | 0.74 | ALOX5AP (0.41) | CNR2GPR119ALOX5APFEN1NAMPT | |
| SCHEMBL25677248 | 0.73 | TLR9 (0.40) | LRRK2 | |
| SCHEMBL30553324 | 0.73 | LIPE (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | CNR2 3959/4885GPR119 769/4885ACACB 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.